| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Forward Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$300.00 |
| 52 Week High | US$882.86 |
| 52 Week Low | US$200.00 |
| Beta | 0 |
| 1 Month Change | -25.00% |
| 3 Month Change | -46.00% |
| 1 Year Change | -61.04% |
| 3 Year Change | -86.22% |
| 5 Year Change | -89.73% |
| Change since IPO | -99.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| FWPA.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -25.1% | 4.7% | 0.7% |
| 1Y | -61.0% | 2.7% | 23.9% |
Return vs Industry: FWPA.Y underperformed the US Biotechs industry which returned 8.1% over the past year.
Return vs Market: FWPA.Y underperformed the US Market which returned 16.8% over the past year.
Price Volatility
| FWPA.Y volatility | |
|---|---|
| FWPA.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FWPA.Y's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine FWPA.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Claus Bo Svendsen | www.forward-pharma.com |
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Forward Pharma A/S Fundamentals Summary
| FWPA.Y fundamental statistics | |
|---|---|
| Market cap | US$7.45m |
| Earnings (TTM) | -US$566.00k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FWPA.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FWPA.Y income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$566.00k |
| Earnings | -US$566.00k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did FWPA.Y perform over the long term?
See historical performance and comparison